SUBSCRIBE Blog with us: BLOGbiotech

GEN News Highlights

• Email
• Print
• Share
• More GEN News Highlights

Oct 29 2009, 11:53 AM EST

Roche’s Initial Phase III Trial Finds Taspoglutide Better than Byetta in Type 2 Diabetes

GEN News Highlights

Roche reports that its type 2 diabetes drug, taspoglutide, showed better reduction of HbA1c levels compared to Lilly’s Byetta. The Phase III T-EMERGE 2 trial is the first in Roche’s late-stage program for taspoglutide.

The study involved 1,189 patient and compared the effects of once-weekly taspoglutide, a glucagon-like peptide-1 (GLP-1) agonist, with twice-daily Byetta. Roche’s T-EMERGE Phase III program will include about 6,000 patients in total. Of the eight trials, four have active comparators including Byetta, sitagliptin, insulin glargine, and pioglitazone.

Roche exercised its taspoglutide licensing option from Ipsen in 2006. Under the terms of the deal, Roche has exclusive rights to develop and market the drug worldwide, except in Japan, where rights are shared with Teijin, and in France, where Ipsen has retained co-marketing rights.

Lilly reported Byetta-related revenues of $115.8 million during the third quarter, up 6% on the same period last year. $77.8 million of the total related to revenues from the company’s Byetta partnership with Amylin Pharmaceuticals. Direct product sales by Lilly amounted to $38 million.

 

♦♦♦
Related News
Confusing Choices for Doctors and Type 2 Diabetes Patients (Oct. 23, 2009)
Novo Nordisk's Type 2 Diabetes Candidate Fares Better in Clinical Trial than Lilly and Amylin's Marketed Drug (June 9, 2009)
Takeda Pulls MAA for Type 2 Diabetes Therapy (June 4, 2009)
BMS and AstraZeneca Expand Dapagliflozin Partnership to Cover Japan (Dec. 8, 2008)
First DPP-4 Inhibitor in the U.S. Approved for Type 2 Diabetes (Oct. 17, 2006)

• Email
• Print
• Share
• More GEN News Highlights

Comment on this News:

Name:
Title:
Comment:
	HELP US FIGHT SPAMMING ROBOTS by answering the following simple question. It will verify you as a legitimate user wishing to post a comment. Thank you for your cooperation.

CAREER CENTER

WEBINARS

PODCASTS

MOST POPULAR